Redwood Investment Management LLC Buys 8,482 Shares of Hologic, Inc. $HOLX

Key Points

• Redwood Investment Management LLC has increased its stake in Hologic, Inc. (NASDAQ: HOLX) by 16.6% in the first quarter, owning 59,589 shares valued at approximately $3.68 million.
• Hologic reported $1.08 earnings per share for the last quarter, surpassing the consensus estimate of $1.05, with revenue reaching $1.02 billion, which is up 1.2% year-over-year.
• Analysts have set various price targets for Hologic, with a consensus average target of $78.00, reflecting a Moderate Buy rating among analysts.

Redwood Investment Management LLC lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 16.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,589 shares of the medical equipment provider's stock after acquiring an additional 8,482 shares during the period. Redwood Investment Management LLC's holdings in Hologic were worth $3,681,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in HOLX. Beverly Hills Private Wealth LLC lifted its stake in shares of Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after buying an additional 180 shares during the last quarter. Allworth Financial LP raised its holdings in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 216 shares during the period. Dark Forest Capital Management LP lifted its position in Hologic by 7.9% during the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after acquiring an additional 223 shares during the last quarter. Baker Avenue Asset Management LP boosted its holdings in shares of Hologic by 0.5% during the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after acquiring an additional 225 shares during the period. Finally, Integrated Advisors Network LLC grew its position in shares of Hologic by 5.4% in the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after purchasing an additional 289 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Price Performance

HOLX stock traded up $0.50 during mid-day trading on Friday, hitting $67.12. The stock had a trading volume of 1,080,191 shares, compared to its average volume of 1,721,362. The firm has a fifty day simple moving average of $66.15 and a 200 day simple moving average of $62.50. The firm has a market capitalization of $14.93 billion, a P/E ratio of 27.85, a P/E/G ratio of 2.44 and a beta of 0.49. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Argus raised Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a report on Monday, August 18th. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Morgan Stanley boosted their target price on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and upped their price target for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Finally, Evercore ISI raised their price target on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.